Surgery to remove the tumor driving excess cortisol is the primary treatment for most forms of hypercortisolism, also known as Cushing’s syndrome. The specific operation, the drugs that might be used before or after it, and the long-term follow-up all depend on where the problem originates: a small tumor in the pituitary gland, a growth in one of the adrenal glands, or a hormone-secreting tumor elsewhere in the body. When surgery cannot fully solve the problem, a growing menu of medications, radiation, and even removal of both adrenal glands can bring cortisol under control. But getting cortisol levels down is only part of the story. High cortisol damages the heart, bones, brain, and metabolism, and some of that damage lingers even after successful treatment.
Why the Cause Determines the Treatment
Hypercortisolism falls into two broad camps. In the more common version, a tumor somewhere is overproducing ACTH, the hormone that tells the adrenal glands to make cortisol. About two-thirds of the time that tumor sits in the pituitary gland, a condition specifically called Cushing’s disease. Less often, the ACTH comes from a tumor in the lung, pancreas, or another organ, which is called ectopic ACTH syndrome. In the second camp, an adrenal gland tumor makes cortisol on its own without any ACTH signal at all. Each scenario calls for a different surgical target, and a different fallback plan if surgery does not cure the problem.
Across all forms, consensus guidelines agree: surgical removal of the responsible tumor is the optimal first treatment whenever it is feasible.1PubMed. Evaluation and treatment of Cushing’s syndrome Second-line options, used when surgery fails, when the tumor cannot be found, or when the patient cannot tolerate an operation, include medication, radiation, and bilateral adrenalectomy.2PubMed Central. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Transsphenoidal Surgery for Pituitary Tumors
When a pituitary tumor is the culprit, the standard operation is transsphenoidal surgery, which reaches the pituitary through the nose and sinuses rather than opening the skull. For small tumors (microadenomas), this approach works well. In one series of 136 patients, the initial remission rate for microadenomas was about 90%, with cortisol levels dropping to very low values almost immediately after the tumor was removed.3PubMed Central. Transsphenoidal surgery for Cushing disease: experience with 136 patients A separate study using an endoscopic technique reported that roughly 84% of patients achieved remission from a single operation at one year or more of follow-up, with remission rates reaching into the mid-90s for microadenomas.4Neurosurgery. Endoscopic Transsphenoidal Surgery for Cushing Disease: Techniques, Outcomes, and Predictors of Remission
The picture is less rosy for larger tumors. Macroadenomas had an initial remission rate of only about 31% in one series, reflecting the difficulty of completely removing a bigger growth.3PubMed Central. Transsphenoidal surgery for Cushing disease: experience with 136 patients Having a visible tumor on an MRI scan dramatically improved the odds of finding it during surgery. Patients who had already undergone a prior operation were about nine times less likely to achieve remission from a repeat surgery.4Neurosurgery. Endoscopic Transsphenoidal Surgery for Cushing Disease: Techniques, Outcomes, and Predictors of Remission That steep drop in success with reoperation is one reason specialists push hard to get the first surgery right.
Adrenalectomy for Adrenal Tumors
When the source of excess cortisol is a benign adrenal adenoma, the treatment is straightforward: remove the affected adrenal gland, usually laparoscopically. The remaining gland takes over cortisol production once it wakes back up, though that recovery period can take months and requires temporary steroid replacement. For cortisol-secreting adrenal adenomas, surgery improved high blood pressure, abnormal cholesterol, and obesity within three months, and diabetes improved within about a year.5PubMed Central. Cardiovascular risk improvement after laparoscopic adrenalectomy in patients with cortisol-secreting adrenal adenoma, a retrospective cohort study Younger patients and those with lower body mass tended to have the best blood pressure outcomes after surgery.
Adrenal cancer (adrenocortical carcinoma) is a different beast entirely. Surgery is still the main treatment, but it often needs to be combined with the drug mitotane, which is toxic to adrenal tissue and serves as a kind of medical backup to keep the remaining or metastatic cancer cells from producing cortisol.
Medical Therapy When Surgery Falls Short
Drugs are not usually the first choice for curing hypercortisolism, but they play several important roles: controlling cortisol before surgery in very sick patients, managing residual disease after incomplete surgery, and serving as the main treatment when no surgery is possible. The medications fall into a few categories based on where in the cortisol pathway they act.
Steroidogenesis Inhibitors
These drugs block the enzymes that the adrenal glands use to manufacture cortisol. The workhorses here are ketoconazole and metyrapone, both decades-old drugs repurposed from other uses. Ketoconazole tends to be preferred in women and in patients without liver disease, while metyrapone is generally favored in men and those without severe potassium imbalances. Both work relatively quickly and are often used as short-term bridges, though long-term use is possible.6PubMed Central. Cushing’s disease: adrenal steroidogenesis inhibitors
Two newer drugs have expanded this category. Levoketoconazole is an isomer of ketoconazole that may be more potent and gentler on the liver. Osilodrostat, approved more recently, blocks cortisol production at lower concentrations than either ketoconazole or metyrapone in laboratory comparisons.7The Journal of Clinical Endocrinology & Metabolism. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study In a meta-analysis of clinical trials, patients taking osilodrostat had dramatically higher odds of normalizing their cortisol levels compared with placebo after two to three months of treatment. The main side effects that were more common than placebo were nausea and joint pain, while serious adverse events and adrenal insufficiency rates were not significantly different between the two groups.8PubMed Central. Efficacy and Safety of Osilodrostat in Managing Cushing’s Syndrome: A Systematic Review and Meta-Analysis Osilodrostat may be particularly useful for long-term treatment because of its once- or twice-daily dosing, compared with the multiple daily doses ketoconazole and metyrapone often require.6PubMed Central. Cushing’s disease: adrenal steroidogenesis inhibitors
Pituitary-Targeted Drugs
If the problem is a pituitary tumor, drugs that target the tumor itself can sometimes reduce ACTH secretion. Pasireotide is a somatostatin analog that binds to receptors found on pituitary tumors producing ACTH. In a phase II trial, about three-quarters of patients had some reduction in cortisol, though only about 17% achieved fully normal levels on the drug alone.9Neuroendocrinology. Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide Cabergoline, a dopamine agonist originally used for other pituitary conditions, normalizes cortisol in roughly 40% of patients at doses ranging from 1 to 7 milligrams per week.10PubMed Central. Update in the medical therapy of Cushing’s disease
Neither drug is a home run on its own, but combining them with each other or with a steroidogenesis inhibitor like ketoconazole has shown better results. In one study, the combination of pasireotide and cabergoline normalized cortisol in half of patients, and adding ketoconazole on top of that achieved biochemical control in most.11PubMed Central. Clinical use of pasireotide for Cushing’s disease in adults This layered approach is common in practice, especially for patients who are not surgical candidates or who have recurred after an operation.
Mifepristone, the Cortisol Blocker
Unlike the other drugs, mifepristone does not reduce how much cortisol your body makes. It blocks the receptor that cortisol binds to, preventing it from acting on tissues. The FDA approved it in 2012 specifically for controlling high blood sugar in Cushing’s syndrome patients who are not surgical candidates or who have not achieved remission from surgery. In its pivotal trial, 60% of patients had meaningful improvements in blood sugar control, and average fasting glucose fell from about 149 to 105 milligrams per deciliter. About 38% saw their diastolic blood pressure drop meaningfully as well.12The Journal of Clinical Endocrinology & Metabolism. Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing’s Syndrome Because the drug blocks cortisol’s action rather than reducing its production, standard cortisol blood tests become unreliable for monitoring, and clinicians have to track progress through clinical signs and glucose levels instead.
Mitotane for Adrenal Cancer
Mitotane occupies a unique niche. Derived from an insecticide, it is directly toxic to adrenal cells and is the mainstay medical treatment for adrenocortical carcinoma, either after surgery or when the cancer has spread. The drug has a notoriously narrow therapeutic window: blood levels need to stay above 14 milligrams per liter to be effective, but above 20 milligrams per liter toxicity becomes a real risk.13PubMed Central. Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art A low-dose approach, starting at about 3 grams per day with regular blood-level monitoring, can reach therapeutic levels in three to five months while keeping side effects manageable for most patients.14The Journal of Clinical Endocrinology & Metabolism. Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer Anyone on mitotane needs lifelong steroid replacement because the drug destroys their adrenal cortex.
Radiation for Persistent Pituitary Tumors
When pituitary surgery fails and medications are not enough, focused radiation can be directed at the remaining tumor. Gamma Knife radiosurgery is the most studied approach. In one series, about 45% of patients achieved cortisol control without any additional medication, and cumulative remission rates climbed to roughly 55% at two years and 72% at three years.15PubMed Central. Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience The main drawback is speed: radiation works gradually over months to years, meaning patients typically need medical therapy to keep cortisol controlled in the interim. Its best targets are small visible tumor remnants, especially those extending into the cavernous sinus where a surgeon cannot easily reach.16International Journal of Cancer Management. Gamma Knife Radiosurgery as a Successful Adjunctive Therapy in Cushing’s Disease: Case Report Pituitary insufficiency is a risk down the road, but it tends to be lower with focused stereotactic techniques than with conventional radiation.
Bilateral Adrenalectomy as a Last Resort
Removing both adrenal glands is the nuclear option for hypercortisolism. It guarantees that cortisol levels will drop, but at the cost of lifelong dependence on replacement steroids for cortisol and aldosterone. It is generally reserved for patients with Cushing’s disease who have failed transsphenoidal surgery, medical therapy, and radiation, or for ectopic ACTH syndrome where the tumor source cannot be found or controlled.
In patients with ectopic Cushing’s from metastatic neuroendocrine tumors, medical treatment alone controlled hormones in only about 13% of those who were medically managed. Nearly half of the patients with drug-resistant disease ultimately underwent bilateral adrenalectomy, which cured their hypercortisolism in every case.17Surgery. Outcomes and management of ectopic Cushing syndrome secondary to neuroendocrine tumors
The biggest worry unique to bilateral adrenalectomy in Cushing’s disease patients is Nelson’s syndrome, where the pituitary tumor, now free from cortisol’s restraining feedback, grows aggressively and produces large amounts of ACTH. A meta-analysis of over 1,300 patients found that roughly one in four developed Nelson’s syndrome after bilateral adrenalectomy, and the risk can persist for decades.18PubMed Central. Prevalence of Nelson’s syndrome after bilateral adrenalectomy in patients with cushing’s disease: a systematic review and meta-analysis About one in five needed treatment specifically for that complication. This is why lifelong pituitary surveillance with MRI is considered essential after the procedure.
Ectopic ACTH Syndrome
When ACTH is being pumped out by a tumor in the lung, thymus, pancreas, or another organ, the ideal treatment is removing that tumor. Among patients without metastases, about half achieved resolution of their Cushing’s syndrome after tumor resection, with the rest split between medical control and eventual bilateral adrenalectomy.17Surgery. Outcomes and management of ectopic Cushing syndrome secondary to neuroendocrine tumors When the tumor has spread, the situation becomes far more complicated. Initial management is almost always medical, using the same steroidogenesis inhibitors discussed earlier, while the multidisciplinary team figures out how to address the cancer itself.19European Journal of Endocrinology. MANAGEMENT OF ENDOCRINE DISEASE: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion Sometimes the ACTH source is never found despite extensive imaging, a situation called occult ectopic ACTH syndrome. These patients may cycle through medical therapy for years, with periodic imaging to try to localize the hidden tumor.
Cardiovascular and Metabolic Recovery After Cure
Bringing cortisol back to normal does not instantly reverse the damage it has caused. High blood pressure, for instance, resolves completely in only a fraction of patients. In one study, about 44% of patients had full remission of their hypertension at their last follow-up evaluation, while about 48% improved but still needed some blood pressure medication.20PubMed Central. Remission of hypertension after surgical cure of Cushing’s syndrome Across multiple studies, the rate of hypertension cure after long-term Cushing’s remission ranged from about 36% to 75%. Diabetes and abnormal cholesterol also improved after remission, but residual risk remained higher than in the general population.21The Journal of Clinical Endocrinology & Metabolism. Long-Term Consequences of Cushing Syndrome: A Systematic Literature Review Even more concerning, the blood-clotting abnormalities associated with Cushing’s syndrome may persist for years after cortisol levels return to normal, keeping cardiovascular risk elevated. Active management of blood pressure, blood sugar, and cholesterol therefore remains important long after the tumor is gone.
Brain, Mood, and Cognitive Recovery
Excess cortisol shrinks the brain, particularly the hippocampus and frontal lobe regions involved in memory, mood, and decision-making. The good news is that surgery helps. A meta-analysis found that after surgical cure, verbal memory, visual memory, executive function, and general intelligence all improved, and depressive symptoms dropped substantially.22The Journal of Clinical Endocrinology & Metabolism. Hippocampal Volume, Cognitive Functions, Depression, Anxiety, and Quality of Life in Patients With Cushing Syndrome Early brain imaging data also shows that cortical volume begins to increase after successful surgery, with the frontal lobe regions recovering most visibly.23PubMed Central. Ultra-high field 7 T MRI localizes regional brain volume recovery following corticotroph adenoma resection and hormonal remission in Cushing’s disease: a case series
The less encouraging part is that recovery is often incomplete. A systematic review found that patients who had higher cortisol levels before treatment and a longer duration of uncontrolled disease were more likely to have lasting cognitive problems even after cortisol returned to normal. Temporal and frontal lobe volumes did not fully recover in many patients.24PubMed. Cognitive decline in Cushing’s syndrome: A systematic review Quality of life improves after treatment but consistently falls short of levels seen in healthy people. Across studies, treated Cushing’s patients reported lower quality of life than controls on every domain measured, from physical functioning to emotional well-being.25The Journal of Clinical Endocrinology & Metabolism. Improvement but No Normalization of Quality of Life and Cognitive Functioning After Treatment of Cushing Syndrome This persistent gap underscores why early diagnosis and treatment matter so much. The longer cortisol stays high, the more irreversible damage accumulates.
Bone Health During and After Treatment
Cortisol is hard on bones. It inhibits bone formation and speeds up bone breakdown, raising fracture risk even at levels of excess that are considered mild. Lowering cortisol is the single most important step for bone recovery, and bone mineral density does tend to improve after successful treatment. However, there are no specific guidelines for osteoporosis management tailored to Cushing’s syndrome. Expert recommendations suggest that additional anti-osteoporotic medications, such as bisphosphonates, may help speed bone density recovery after cure and prevent further loss in patients who have not yet achieved remission.26PubMed Central. Cushing’s disease and bone Bone density scans before and after treatment help guide those decisions.
When the Cause Is Prescribed Steroids
By far the most common cause of hypercortisolism is not a tumor at all. It is prescribed corticosteroids like prednisone, dexamethasone, or hydrocortisone taken for inflammatory or autoimmune conditions. The treatment here is conceptually simple but practically tricky: taper the steroids down slowly enough that the body’s own cortisol production has time to restart. The adrenal glands can go dormant after weeks to months of external steroid use, and stopping abruptly can trigger an adrenal crisis with dangerously low cortisol.
The standard approach is to reduce from a higher dose fairly quickly down to a near-physiological dose (roughly equivalent to what the body would make on its own), and then slow the taper considerably to allow the adrenal glands to wake up.27PubMed Central. The Glucocorticoid Taper: A Primer for the Clinicians There is ongoing research testing whether some patients can actually stop steroids abruptly rather than tapering, though that work has not yet yielded definitive results.28PLoS ONE. Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST” (Taper Or Abrupt Steroid STop) multicenter trial For now, gradual tapering under medical supervision remains the standard of care. Anyone on long-term steroids for another condition should not adjust their dose on their own.
Pregnancy and Cushing’s Syndrome
Cushing’s syndrome during pregnancy is exceptionally rare, with fewer than 200 cases reported in the medical literature. It is also hard to diagnose, because normal pregnancy raises cortisol levels two- to three-fold and can produce Cushing’s-like symptoms such as stretch marks and fluid retention. When active disease is present, the stakes are high: maternal complications include high blood pressure, preeclampsia, diabetes, fractures, and in rare cases heart failure or death. Fetal risks include premature birth, growth restriction, and stillbirth.29PubMed. Management of Cushing’s syndrome during pregnancy: solved and unsolved questions Treatment decisions involve weighing the risks of surgery during pregnancy against the risks of uncontrolled cortisol. When the source is an adrenal adenoma, adrenalectomy in the second trimester is sometimes performed. Medical therapy, particularly metyrapone, has been used in pregnancy, though the evidence base is almost entirely from case reports.
Treating Hypercortisolism in Children
Cushing’s disease in children is managed much like adult cases, with transsphenoidal surgery as the first-line treatment. The major additional concern is growth. Excess cortisol suppresses growth hormone and can stunt height, so children who achieve remission often need growth hormone replacement. Long-term follow-up of pediatric patients shows improvements in growth, weight, bone density, and mental health after successful treatment, though these measures may not fully return to normal.30PubMed Central. Long-term outcomes of children treated for Cushing’s disease: a single center experience Post-surgical adrenal insufficiency in children requires careful glucocorticoid replacement, with doses adjusted as the child grows.
Emerging Drugs on the Horizon
The treatment landscape continues to evolve. Relacorilant is a selective glucocorticoid receptor antagonist in development that, unlike mifepristone, does not also block progesterone receptors, potentially making it safer for women and reducing certain hormonal side effects. Early data suggest it may effectively control blood pressure and blood sugar in Cushing’s syndrome with a good safety profile.31PubMed Central. Medical Treatment of Cushing’s Disease: An Overview of the Current and Recent Clinical Trials Other experimental compounds targeting adrenal steroidogenesis through different mechanisms are also in various stages of clinical testing. For a condition that had almost no approved drugs a decade ago, the pipeline is now meaningfully active. Whether these newer agents will offer enough advantage over current options to change practice is something only longer-term trial data will answer.